Entecavir-Associated Thrombocytopenia: A Case Report and Review of the Pathophysiology, Diagnosis, and Treatment of a Rare but Reversible Cause of Thrombocytopenia

Figure 1

Course of drug-induced immune thrombocytopenia in a patient treated with entecavir. Entecavir was prescribed for prophylaxis to prevent HBV reactivation before initiating rituximab therapy. Starting from day 5 of treatment, the patient reported having easy bruising and bleeding from the oral cavity. She came to the office on day 7, and her platelet count was 7000 per cubic millimeter. Entecavir was discontinued immediately, and 3 units of apheresed platelets and IV immunoglobulin were given (days 7–11). The platelet counts improved and normalized in a week.